MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 29, 2005; DOI: 10.1124/mol.105.015446


0026-895X/05/6806-1669-1677$20.00
Mol Pharmacol 68:1669-1677, 2005

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.015446v1
68/6/1669    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Criado, M.
Right arrow Articles by Sala, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Criado, M.
Right arrow Articles by Sala, F.

Mutations of a Conserved Lysine Residue in the N-Terminal Domain of {alpha}7 Nicotinic Receptors Affect Gating and Binding of Nicotinic Agonists

Manuel Criado, José Mulet, José A. Bernal, Susana Gerber, Salvador Sala, and Francisco Sala

Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-Consejo Superior de Investigaciones Cientificas, Alicante, Spain

Activation of nicotinic acetylcholine receptors is initiated by binding of agonists, and as a consequence, specific domains transmit the chemical signal to the channel gate through a sequence of conformational changes. Recent high-resolution structural data from a snail acetylcholine binding protein have shown that the side chain of a lysine residue, located in the {beta}-strand {beta}7 and strictly conserved in {alpha} subunits of nicotinic receptors, systematically moves upon agonist binding, suggesting that it might be involved in both binding and gating. To test this hypothesis in neuronal nicotinic receptors, Lys145 was substituted by other amino acids in the {alpha}7 nicotinic receptor, and expression levels and electrophysiological responses for several nicotinic agonists and antagonists were determined. Substitutions of Lys145 showed a variety of functional effects: 1) strong reductions in the functional responses to acetylcholine, nicotine, and dimethylphenylpiperazinium, the latter becoming an antagonist; 2) increases in the agonist EC50 values (up to 80-fold with acetylcholine); 3) heterogeneous behavior of the different agonists, with epibatidine and cytisine being less affected by the substitutions; 4) decreases of agonist affinities for the desensitized receptors; and 5) small changes in the affinity of nicotinic antagonists. It is concluded that the presence of a polar or positively charged side chain at this position improves the gating function with acetylcholine and nicotine, although the lysine side chain seems to be necessary for retaining the binding properties of acetylcholine. The results are compatible with the involvement of Lys145 in the early steps of channel activation by acetylcholine.


Received June 1, 2005; accepted August 29, 2005

Address correspondence to: Dr. Francisco Sala, Instituto de Neurociencias de Alicante, Universidad Miguel Hernández-CSIC, Apartado 18, 03550-Sant Joan d'Alacant, Alicante, Spain. E-mail: fsala{at}umh.es




This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
G. T. Young, L. M. Broad, R. Zwart, P. C. Astles, M. Bodkin, E. Sher, and N. S. Millar
Species Selectivity of a Nicotinic Acetylcholine Receptor Agonist Is Conferred by Two Adjacent Extracellular beta4 Amino Acids that Are Implicated in the Coupling of Binding to Channel Gating
Mol. Pharmacol., February 1, 2007; 71(2): 389 - 397.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics